AbCellera Biologics (ABCL) Stock Forecast & Price Target

AbCellera Biologics is supported by a differentiated antibody-discovery platform that targets difficult, high-value biology, including complex transmembrane proteins, multispecifics, and antibody-drug conjugates, which creates meaningful long-term optionality beyond a single asset. Its outlook is strengthened by a broad pipeline with two drug candidates in clinical development, two more in IND/CTA-enabling work, and more than 20 active discovery programs, while 2Q26 cash and marketable securities of $565M provide balance-sheet flexibility. The recent Jazz agreement adds $56 million upfront, plus a potential $28 million within 12 months, and should lift revenues, earnings, and operating cash through fiscal 2027E as downstream stakes in 35 external programs and 12 clinical programs expand.

AbCellera Biologics is viewed negatively because its lead programs remain in early-stage development, leaving substantial clinical uncertainty around whether the therapeutic rationale and initial proof-of-concept data will hold up in later trials. As a clinical-stage biotechnology company with only two drug candidates in clinical development, two more in IND/CTA-enabling activities, and more than 20 active discovery programs, it still lacks the diversification and validation that would reduce execution risk. The dependence on unproven programs across complex targets and novel modalities makes future development outcomes highly uncertain, which weakens the fundamental case for the stock.